Watch for topline ECLIPSE 1 Phase 3 data in Q4 2026, which is a pivotal catalyst for the CHD program. The Gilead collaboration validates the PRO-XTEN platform but adds no near-term revenue. Monitor cash burn rate and any updates on VIR-5500 pivotal trial initiation in 2027.
Drugs in focus
VIR drug pipeline →elebsiran
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 ECLIPSE 1 results are positive, regulatory filings could follow in 2027, with potential FDA approval in 2027-2028 given the Breakthrough Therapy designation enabling expedited review.
- Next catalyst
- None dated
What to watchThe pivotal Phase 3 ECLIPSE 1 topline results for elebsiran plus tobevibart in chronic hepatitis delta will be presented as a late-breaking oral at AASLD on November 8, 2026, with an investor call on November 9. Positive data would support regulatory filings and validate the combination against bulevirtide; negative or mixed results would severely damage the company's lead program thesis. The stock surged ~11% on November 6 ahead of the readout, reflecting anticipation.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $11.02entry
- T+1 · 11d ago +10.80%α +10.49% · $12.21
- T+5 · 5d ago +9.98%α +6.69% · $12.12
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vir Biotechnology reported Q3 2026 net loss of $96.3M ($0.57 per share), narrower than the $163.1M loss in Q3 2025, driven by a $75M non-recurring milestone expense in the prior year. The company ended the quarter with $901.3M in cash and investments, entered a Gilead collaboration for up to $1.74B in milestones, and expects topline Phase 3 ECLIPSE 1 data in Q4 2026.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $96.3M ($0.57 per share) vs $163.1M ($1.17 per share) in Q3 2025
- Cash, cash equivalents and investments of $901.3M as of September 30, 2026, a decrease of $106.5M during Q3
- Entered collaboration with Gilead for three PRO-XTEN dual-masked TCE candidates; received $90M upfront including $25M equity investment at 30% premium
- VIR-5500 received FDA Fast Track designation and achieved proof of concept; pivotal trials expected to begin in 2027
- Topline data from Phase 3 ECLIPSE 1 trial for chronic hepatitis delta expected in Q4 2026
- Appointed Aziz Sawaf as CFO, David Liu as CMO, and Suzanne Topalian to the Board
Financial Impact
Net loss improved by $66.8M YoY; cash burn of $106.5M in Q3; Gilead deal provides $90M upfront with potential $1.74B in milestones
Risk Factors
- Phase 3 ECLIPSE 1 data readout in Q4 2026 carries binary risk for the CHD program
- Cash burn of $106.5M per quarter implies runway into H2 2028, but no revenue from pipeline
- Gilead collaboration milestones are contingent on preclinical and clinical success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-070148 |
| Document: vir-20261104.htm | 0001628280-26-070148 |
| Document: 0001628280-26-070148-index-headers.html | 0001628280-26-070148 |
| Document: 0001628280-26-070148-index.html | 0001628280-26-070148 |
| Document: 0001628280-26-070148.txt | 0001628280-26-070148 |
| 8-K Data (Synthetic) | 0001628280-26-070148 |
Track record
36 reports on VIR
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Viewing Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers